Rev Neurol (Paris) 2008, 164:595–604. 31. Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S, Porchet N, Escande F: Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors–towards individualized tumor treatment? OICR-9429 in vivo Neuro Oncol 2010, 12:490–499.PubMed 32. Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J: Efficacy of temozolomide is correlated with

1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo) 2007, 47:341–349. discussion 350.CrossRef 33. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al.: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739–744.PubMedCrossRef 34. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al.: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765–773.PubMedCrossRef 35. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta

Neuropathol 2008, 116:597–602.PubMedCrossRef 36. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, et al.: selleck chemicals Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261–265.PubMedCrossRef 37. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, et al.: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent

dioxygenases. Cancer Cell 2011, 19:17–30.PubMedCrossRef 38. Sonoda Y, Tominaga T: 2-hydroxyglutarate accumulation caused by IDH mutation is involved in the formation of malignant gliomas. Expert Rev Neurother 2010, 10:487–489.PubMedCrossRef 39. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, et al.: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Montelukast Sodium Neurology 2010, 75:1560–1566.PubMedCrossRef 40. Matsubara H, Takeuchi T, Nishikawa E, Yanagisawa K, Hayashita Y, Ebi H, Yamada H, Suzuki M, Nagino M, Nimura Y, et al.: Apoptosis induction by antisense oligonucleotides against miR-17–5p and miR-20a in lung cancers overexpressing miR-17–92. Oncogene 2007, 26:6099–6105.PubMedCrossRef 41. Jeang KT: Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction? Oncotarget 2010, 1:453–456.PubMed 42. Moore LM, Zhang W: Targeting selleck compound miR-21 in glioma: a small RNA with big potential. Expert Opin Ther Targets 2010, 14:1247–1257.PubMedCrossRef 43. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, Jia ZF, Yang WD, Wang GX, Jiang T, You YP, et al.: MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma.